| Symbol | EVMN |
|---|---|
| Name | EVOMMUNE, INC. |
| Sector | UNDEFINED |
| Region | UNDEFINED |
| Industry | Pharmaceutical Preparations |
| Address | 1841 PAGE MILL ROAD,SUITE 100, PALO ALTO, California, 94304, United States |
| Telephone | +1 925 247-4487 |
| Fax | — |
| — | |
| Website | — |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0002044725 |
| Description | Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis and ulcerative colitis. Among our portfolio of programs, we currently have two product candidates, EVO756 and EVO301, in Phase 2 trials. We are initially developing EVO756 for the treatment of CSU and AD, and EVO301 for the treatment of AD and UC. We see broad expansion potential for both programs across additional chronic inflammatory diseases. We also intend to advance additional preclinical programs into clinical development. Additional info from NASDAQ: |
Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights
Read moreNew Form 424B3 - Evommune, Inc. <b>Filed:</b> 2026-05-07 <b>AccNo:</b> 0001193125-26-212038 <b>Size:</b> 1 MB
Read moreNew Form EFFECT - Evommune, Inc. <b>Filed:</b> 2026-04-24 <b>AccNo:</b> 9999999995-26-001330 <b>Size:</b> 1 KB
Read moreNew Form 424B3 - Evommune, Inc. <b>Filed:</b> 2026-04-24 <b>AccNo:</b> 0001193125-26-177356 <b>Size:</b> 756 KB
Read moreNew Form ARS - Evommune, Inc. <b>Filed:</b> 2026-04-21 <b>AccNo:</b> 0001193125-26-166761 <b>Size:</b> 5 MB
Read moreNew Form DEFA14A - Evommune, Inc. <b>Filed:</b> 2026-04-21 <b>AccNo:</b> 0001193125-26-166755 <b>Size:</b> 2 MB
Read moreNew Form DEF 14A - Evommune, Inc. <b>Filed:</b> 2026-04-21 <b>AccNo:</b> 0001193125-26-166747 <b>Size:</b> 2 MB
Read morePatel Jeegar Pravinkumar 🟢 acquired 69.3K shares (1 derivative) of Evommune, Inc. (EVMN) at $26.77 ($1.9M) Transaction Date: Apr 16, 2026 | Filing ID: 000003
Read moreDrew Janice Suzann 🟢 acquired 73.9K shares (1 derivative) of Evommune, Inc. (EVMN) at $26.77 ($2.0M) Transaction Date: Apr 16, 2026 | Filing ID: 000003
Read moreBauer Eugene 🟢 acquired 51.1K shares (1 derivative) of Evommune, Inc. (EVMN) at $26.77 ($1.4M) Transaction Date: Apr 16, 2026 | Filing ID: 000003
Read more